FPH Stock Overview
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide.
No risks detected for FPH from our risk checks.
Fisher & Paykel Healthcare Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$33.33|
|52 Week High||NZ$36.55|
|52 Week Low||NZ$27.10|
|1 Month Change||6.79%|
|3 Month Change||1.59%|
|1 Year Change||-6.14%|
|3 Year Change||156.39%|
|5 Year Change||306.46%|
|Change since IPO||7,306.67%|
Recent News & Updates
This Is The Reason Why We Think Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) CEO Deserves A Bump Up To Their Compensation
The impressive results at Fisher & Paykel Healthcare Corporation Limited ( NZSE:FPH ) recently will be great news for...
Is Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Worth NZ$31.6 Based On Its Intrinsic Value?
Does the August share price for Fisher & Paykel Healthcare Corporation Limited ( NZSE:FPH ) reflect what it's really...
Do Fisher & Paykel Healthcare's (NZSE:FPH) Earnings Warrant Your Attention?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
|FPH||NZ Medical Equipment||NZ Market|
Return vs Industry: FPH exceeded the NZ Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: FPH underperformed the NZ Market which returned -4.7% over the past year.
|FPH Average Weekly Movement||4.1%|
|Medical Equipment Industry Average Movement||8.0%|
|Market Average Movement||3.6%|
|10% most volatile stocks in NZ Market||7.0%|
|10% least volatile stocks in NZ Market||2.4%|
Stable Share Price: FPH is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: FPH's weekly volatility (4%) has been stable over the past year.
About the Company
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system.
Fisher & Paykel Healthcare Fundamentals Summary
|FPH fundamental statistics|
Is FPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FPH income statement (TTM)|
|Cost of Revenue||NZ$709.60m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0|
|Net Profit Margin||26.54%|
How did FPH perform over the long term?See historical performance and comparison
1.3%Current Dividend Yield
Does FPH pay a reliable dividends?See FPH dividend history and benchmarks
|Fisher & Paykel Healthcare dividend dates|
|Ex Dividend Date||Dec 02 2021|
|Dividend Pay Date||Dec 15 2021|
|Days until Ex dividend||1 day|
|Days until Dividend pay date||14 days|
Does FPH pay a reliable dividends?See FPH dividend history and benchmarks
Is Fisher & Paykel Healthcare undervalued compared to its fair value and its price relative to the market?
Share Price vs. Fair Value
Below Fair Value: FPH (NZ$33.33) is trading above our estimate of fair value (NZ$25.76)
Significantly Below Fair Value: FPH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: Insufficient data to calculate FPH's PE Ratio to determine if it is good value compared to the Oceanic Medical Equipment industry average.
PE vs Market: Insufficient data to calculate FPH's PE Ratio to determine if it is good value compared to the NZ market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: Insufficient data to calculate FPH's PB Ratio to determine if it is good value.
How is Fisher & Paykel Healthcare forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FPH's forecast earnings growth (2% per year) is below the savings rate (2.1%).
Earnings vs Market: FPH's earnings (2% per year) are forecast to grow slower than the NZ market (6.6% per year).
High Growth Earnings: FPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: FPH's revenue (3.6% per year) is forecast to grow slower than the NZ market (4.6% per year).
High Growth Revenue: FPH's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FPH's Return on Equity is forecast to be high in 3 years time (22.4%)
How has Fisher & Paykel Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FPH has high quality earnings.
Growing Profit Margin: FPH's current net profit margins (26.5%) are higher than last year (24.4%).
Past Earnings Growth Analysis
Earnings Trend: FPH's earnings have grown significantly by 27.2% per year over the past 5 years.
Accelerating Growth: FPH's earnings growth over the past year (32.9%) exceeds its 5-year average (27.2% per year).
Earnings vs Industry: FPH earnings growth over the past year (32.9%) underperformed the Medical Equipment industry 57.5%.
Return on Equity
High ROE: FPH's Return on Equity (32.7%) is considered high.
How is Fisher & Paykel Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: FPH's short term assets (NZ$867.7M) exceed its short term liabilities (NZ$314.3M).
Long Term Liabilities: FPH's short term assets (NZ$867.7M) exceed its long term liabilities (NZ$140.3M).
Debt to Equity History and Analysis
Debt Level: FPH has more cash than its total debt.
Reducing Debt: FPH's debt to equity ratio has reduced from 11.4% to 4.5% over the past 5 years.
Debt Coverage: FPH's debt is well covered by operating cash flow (739.6%).
Interest Coverage: FPH's interest payments on its debt are well covered by EBIT (220.5x coverage).
What is Fisher & Paykel Healthcare current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: FPH's dividend (1.32%) isn’t notable compared to the bottom 25% of dividend payers in the NZ market (2.78%).
High Dividend: FPH's dividend (1.32%) is low compared to the top 25% of dividend payers in the NZ market (5%).
Stability and Growth of Payments
Stable Dividend: FPH is not paying a notable dividend for the NZ market, therefore no need to check if payments are stable.
Growing Dividend: FPH is not paying a notable dividend for the NZ market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: FPH is not paying a notable dividend for the NZ market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FPH's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lewis Gradon (60 yo)
Mr. Lewis G. Gradon has been the Chief Executive Officer, Managing Director & Executive Director at Fisher & Paykel Healthcare Corporation Limited since April 1, 2016. He served as the Senior Vice Presiden...
CEO Compensation Analysis
Compensation vs Market: Lewis's total compensation ($USD2.71M) is about average for companies of similar size in the NZ market ($USD3.71M).
Compensation vs Earnings: Lewis's compensation has increased by more than 20% in the past year.
Experienced Management: FPH's management team is seasoned and experienced (5.6 years average tenure).
Experienced Board: FPH's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Fisher & Paykel Healthcare Corporation Limited's employee growth, exchange listings and data sources
- Name: Fisher & Paykel Healthcare Corporation Limited
- Ticker: FPH
- Exchange: NZSE
- Founded: 1934
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: NZ$19.043b
- Shares outstanding: 577.05m
- Website: https://www.fphcare.com
Number of Employees
- Fisher & Paykel Healthcare Corporation Limited
- 15 Maurice Paykel Place
- East Tamaki
- New Zealand
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 09:14|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.